glp-1 receptor agonists adverse effects as Treatments for Type 2 Diabetes Size:60 GLP-1 (S) peptide pfizer glp 1 agonist

glp-1 receptor agonists adverse effects as Treatments for Type 2 Diabetes Size:60 GLP-1 (S) peptide pfizer glp 1 agonist

pfizer glp 1 agonist The challenge of developing oral alternatives to Ozempic, Wegovy and Mounjaro Oral GLP-1 Drug Danuglipron to –

they work best when they support, not replace, the fundamentals of metabolic health

GLP-1 (S) peptide

Size:60

For example, in clinical trials of semaglutide 2.4 mg (Wegovy), nausea occurred in approximately 44% of patients, while rates for tirzepatide and other GLP-1s vary: Nausea : Often described as mild queasiness, particularly after eating, though some patients experience more pronounced nausea Bloating and abdominal fullness : A sensation of delayed digestion or food sitting heavily in the stomach Changes in bowel habits : Constipation affects approximately 15-30% of patients (varying by medication and dose), while some experience diarrhea or alternating patterns [1] [4] Decreased appetite : Beyond simple fullness, many report a fundamental shift in food thoughts, with reduced cravings and less mental preoccupation with eating Some patients report fatigue or low energy , particularly during the initial weeks